NCT04421196

Opioid-free Total Hip Arthroplasty

Withdrawn NA Last updated 21 September 2022

What this trial tests

NA trial testing Exclusion of opioid analgesics in Hip Osteoarthritis. Withdrawn.

Timeline

15 September 2022

Primary endpoint
1 September 2023

1 December 2023

Quick facts

Lead sponsor	Johns Hopkins University
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Start date	15 September 2022
Primary completion	1 September 2023
Estimated completion	1 December 2023

Drugs / interventions tested

• Exclusion of opioid analgesics

Conditions studied

• Hip Osteoarthritis — all drugs for Hip Osteoarthritis →

Sponsor

Johns Hopkins University

Who can join

Eligibility, any sex, with Hip Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of investigators' proposed study is to demonstrate that the following two cohorts undergoing total hip arthroplasty will have equivalent visual analog scale (VAS) scores up to 3 months post-operatively: one that is administered a modified multimodal analgesic pathway without opioids and the other administered the current standard multimodal analgesic pathway used at Johns Hopkins Bayview Hospital (which includes opioids). The secondary objective is to demonstrate that these cohorts will also have equivalent functional outcomes as determined by both objective measures (such as hip range of motion) and patient-reported outcome measures, such as the Hip Disability and Osteoarthritis Outcome Score (HOOS) and the University of California at Los Angeles (UCLA) activity score.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.